Innovent Biologics announced it will showcase multiple clinical and preclinical results for its obesity and metabolic disease treatments, including mazdutide and next-generation drugs, at the 2026 American Diabetes Association Scientific Sessions. The presentations cover studies on adults and adolescents with obesity and type 2 diabetes, highlighting mazdutide's benefits in weight loss and glycemic control. Innovent also revealed data on new oral GLP-1 receptor agonists and other innovative therapies aimed at improving treatment tolerability and effectiveness. These developments position Innovent as a rising leader in obesity and metabolic disease treatment globally.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
AIB Data Centers Inc. is considered a speculative buy with a $3.50 price target based on its 65 MW energized capacity. The investment case depends heavily on securing a single anchor lease at its CLT-01 facility, which would validate its business mod...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
